Cardiac Amyloidosis: An Underdiagnosed, Not Rare Disease - Grand Rounds 15 Feb 2023

Explore cardiac amyloidosis, an underdiagnosed condition, in this comprehensive Grand Rounds presentation by Dr. Kevin Michael Alexander, Assistant Professor of Cardiovascular Medicine at Stanford. Delve into clinical subtypes, pathophysiology, mechanisms, and molecular studies of this disease. Discover the importance of early diagnosis, imaging techniques, biopsy procedures, and screening algorithms. Learn about current treatments, including FDA-approved medications and ongoing clinical trials. Gain insights into challenges in treatment access, research opportunities, and the significance of amyloidosis in diverse populations. Understand the role of machine learning and AI in diagnosis, environmental risk factors, and the potential of gene editing. Address common questions about beta blockers, ACE inhibitors, biomarkers, genetic testing, and recommendations for primary care doctors in managing this condition.

Welcome
Black History Month
Virtual Grand Rounds
Presentation Mode
Amyloidosis
Clinical subtypes
Path of physiology
Mechanisms
Direct Cardiotoxicity
Molecular Studies
Treatment
Early Diagnosis
Time is of the Essence
Rochester Minnesota
Amyloidosis Metaanalysis
Not Rare
Diagnosis
Imaging
Biopsy
Mass spectrometry
Nuclear centigraphy
Extra cardiac clues
Screening algorithm
Why is it important
What happens in HTTR
Treatments for HTTR
Landmark Study
subgroup analysis
silencers
Zynotarsin
Current FDA labeling
Clinical trials
Gene editing
Challenges
Treatment Access
Research
Summary
Thank you
I would say two things
modalities that are necessary
machine learning AI
environmental risk factors
Amyloidosis and blacks
Advanced stages of disease
Finding milder patients
Safety duration of effect
Why are beta blockers and ACE inhibitors ineffective
Are there specific sensitive immune biomarkers being studied
Do you collect exosome data
Do you recommend genetic testing
Is there a treatment
For primary care doctors
Closing remarks